SciELO - Scientific Electronic Library Online

 
vol.31 issue2Mental training: a tool needed for surgeonsThrombotic microangiopathy in Systemic Lupus Erythematosus: three cases report author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Iatreia

Print version ISSN 0121-0793

Abstract

NIETO-RIOS, John Fredy et al. Metformin lactic acidosis. Report of two cases. Iatreia [online]. 2018, vol.31, n.2, pp.191-196. ISSN 0121-0793.  http://dx.doi.org/10.17533/udea.iatreia.v31n2a07.

Metformin lactic acidosis. Report of two cases Metformin is recommended as a first-line treatment for patients with diabetes mellitus type 2; it has a cardiovascular protective effect, and low risk of hypoglycemia. However, a severe but infrequent complication of its use is lactic acidosis, which has high morbidity and mortality rates. The estimated incidence of metformin lactic acidosis is 7,4 cases per 100.000 patients per year. Main risk factors are acute or chronic renal disease, congestive heart failure, hepatic failure, and concomitant use of drugs that affect metformin clearance or energy metabolism. Treatment includes hydration with crystalloids, support measures, and intravenous bicarbonate. Renal replacement therapy has been successful for treating metformin-associated lactic acidosis, but there are still no clear indications for it, because metformin is a partially dialyzable molecule and prolonged hemodialysis is required to reduce its levels sufficiently. Despite current treatment, mortality remains high. Early diagnosis and prompt multidisciplinary support are essential to improve outcome in these patients.

Keywords : Acidosis, Lactic; Diabetes Mellitus; Dialysis; Metformin; Renal Insufficiency.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )